Glaxo Sues Spectrum Pharma Over Imitrex Patent Challenge
Glaxo filed its lawsuit on Friday to prevent Spectrum from proceeding with the commercialization of its product. This action formally initiates the patent challenge process under the Hatch-Waxman Act.
The venue of the lawsuit and the attorneys involved were not immediately available.
In October of last year, Spectrum submitted an Abbreviated New Application (ANDA) with the U.S. Food and Drug Administration containing a Paragraph IV...
To view the full article, register now.